Serum insulin-like growth factor-I is negatively associated with serum adiponectin in type 2 diabetes mellitus

Growth Hormone and IGF Research

Volumn 21, Issue 5, 2011, Pages 268-271

  Kanazawa, Ippei ^a   Yamaguchi, Toru ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Adiponectin; Dehydroepiandrosterone sulfate; HbA1c; Insulin like growth factor I; Type 2 diabetes mellitus1

Indexed keywords

ADIPONECTIN; CREATININE; HEMOGLOBIN A1C; PRASTERONE SULFATE; SOMATOMEDIN C;

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED;

EID: 80052555421     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.07.004     Document Type: Article

References (42)

1. Vaessen N., Heutink P., Janssen J.A., Witteman J.C., Testers L., Hofman A., Lamberts S.W., Oostra B.A., Pols H.A., van Duijn C.M. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001, 50:637-642.
2. Haffner S.M., Moss S.E., Klein B.E., Klein R. Sex hormones and DHEA-SO4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care 1996, 19:1045-1050.
3. Moses A.C., Young S.C., Morrow L.A., O'Brien M., Clemmons D.R. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996, 45:91-100.
4. Coleman D.L., Leiter E.H., Schwizer R.W. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 1982, 31:830-833.
5. Labrie F., Diamond P., Cusan L., Gomez J.L., Belanger A., Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab. 1997, 82:3498-3505.
6. Sugimoto T., Nishiyama K., Kuribayashi F., Chihara K. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J. Bone Miner. Res. 1997, 12:1272-1279.
7. Berryman D.E., Christiansen J.S., Johannsson G., Thorner M.O., Kopchick J.J. Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth horm. IGF Res. 2008, 18:455-471.
8. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., Tataranni P.A. Hypoadiponectemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001, 86:1930-1935.
9. Combs T.P., Berg A.H., Obici S., Scherer P.E., Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 2001, 108:1875-1881.
10. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001, 7:947-953.
11. Kawano J., Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J. Cardiometab. Syndr. 2009, 4:44-49.
12. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur. J. Endocrinol. 2009, 160:265-273.
13. Baratta R., Amato S., Degano C., Farina M.G., Patane G., Vigneri R., Frittitta L. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J. Clin. Endocrinol. Metab. 2004, 89:2665-2671.
14. Isobe T., Saitoh S., Takagi S., Takeuchi H., Chiba Y., Katoh N., Shimamoto K. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur. J. Endocrinol. 2005, 153:91-98.
15. Adamczak M., Rzepka E., Chudek J., Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin. Endocrinol. 2005, 62:114-118.
16. Gannage-Yared M.H., Khalife S., Semaan M., Fares F., Jambart S., Halaby G. Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur. J. Endocrinol. 2006, 155:167-176.
17. Shimizu H., Oh I.S., Tsuchiya T., Ohtani K.I., Okada S., Mori M. Pioglitazone increases circulating adiponectin levels and subsequently reduced TNF-alpha levels in type 2 diabetic patients: a randomized study. Diabet. Med. 2006, 23:253-257.
18. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos. Int. 2007, 18:1675-1681.
19. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Serum osteocalcin/bone specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif. Tissue Int. 2009, 85:228-234.
20. Kanazawa I., Yamaguchi T., Sugimoto T. Serum Insulin-like growth factor-I is a maker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos. Int. 2011, 22:1191-1198.
21. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Kurioka S., Yano S., Sugimoto T. Serum DHEA-S level is associated with the presence of atherosclerosis in postmenopausal women with type 2 diabetes mellitus. Endocr. J. 2008, 55:667-675.
22. Yamaza H., Komatsu T., To K., Toyama H., Chiba T., Higami Y., Shimokawa I. Involvement of insulin-like growth factor-I in the effect of caloric restriction: regulation of plasma adiponectin and leptin. J. Gerontol. A Biol. Sci. Med. Sci. 2007, 62:27-33.
23. Kanety H., Hemi R., Ginsberg S., Pariente C., Yissachar E., Barhod E., Funahashi T., Laron Z. Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity. Eur. J. Endocrinol. 2009, 161:837-844.
24. Fukuda I., Hizuka N., Ishikawa Y., Itoh E., Yasumoto K., Murakami Y., Sata A., Tsukada J., Kurimoto M., Okubo Y., Takano K. Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth horm. IGF Res. 2004, 14:449-454.
25. Watanabe S., Tamura T., Ono K., Horiuchi H., Kimura T., Kita T., Furukawa Y. Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur. J. Heart Fail. 2010, 12:1214-1222.
26. Engstrom B.E., Burman P., Holdstock C., Karlsson F.A. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J. Clin. Endocrinol. Metab. 2003, 88:5193-5198.
27. Makimura H., Stanley T.L., Chen C.Y., Branch K.L., Grinspoon S.K. Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor. Growth Horm. IGF Res. 2011, 21:155-159.
28. Akishita M., Fukai S., Hashimoto M., Kameyama Y., Nomura K., Nakamura T., Ogawa S., Iijima K., Eto M., Ouchi Y. Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens. Res. 2010, 33:587-591.
29. Nishizawa H., Shimomura I., Kishida K., Maeda N., Kuriyama H., Nagaretani H., Matsuda M., Kondo H., Furuyama N., Kihara S., Nakamura T., Tochino Y., Funahashi T., Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51:2734-2741.
30. Cui J., Wu X., Andrel J., Falkner B. Relationships of total adiponectin and molecular weight fractions of adiponectin with free testosterone in African men and premenopausal women. J. Clin. Hypertens. 2010, 12:957-963.
31. Boulware S.D., Tamborlane W.V., Matthews L.S., Sherwin R.S. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am. J. Physiol. 1992, 262:E130-E133.
32. Paolisso G., Tagliamonte M.R., Rizzo M.R., Carella C., Gambardella A., Barbieri M., Varricchio M. Low plasma insulin-like growth factor-1 concentrations predict worsening of insulin-mediated glucose uptake in older people. J. Am. Geriatr. Soc. 1999, 47:1312-1318.
33. Rosato M.T., Schneider S.H., Shapses S.A. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif. Tissue Int. 1998, 63:107-111.
34. Rieu M., Binoux M. Serum levels of insulin-like growth factor (IGF) and IGF binding protein in insulin-dependent diabetics during an episode of severe metabolic decompensation and the recovery phase. J. Clin. Endocrinol. Metab. 1985, 60:781-785.
35. Frystyk J., Skjaerbaek C., Vestbo E., Fisker S., Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab. Res. Rev. 1999, 15:314-322.
36. Dillon J.S., Yaney G.C., Zhou Y., Voilley N., Bowen S., Chipkin S., Bliss C.R., Schultz V., Schuit F.C., Prentki M., Waxman D.J., Corkey B.E. Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes 2000, 49:2012-2020.
37. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 1992, 117:807-811.
38. Ueshiba H., Shimizu Y., Hiroi N., Yakushiji F., Shimojo M., Tsuboi K., Miyachi Y. Decreased steroidogenic enzyme 17,20-lyase and increased 17-hydroxylase activities in type 2 diabetes mellitus. Eur. J. Endocrinol. 2002, 16:375-380.
39. Yamauchi A., Takei I., Nakamoto S., Ohashi N., Kitamura Y., Tokui M., Nakano S., Takayama S., Kasuga A., Katsukawa F., Saruta T. Hyperglycemia decreases dehydroepiandrosterone in Japanese male with impaired glucose tolerance and low insulin response. Endocr. J. 1996, 43:285-290.
40. Tchernof A., Despres J.P., Dupont A., Belanger A., Nadeau A., Prud'homme D., Moorjani S., Lupien P.J., Labrie F. Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. Diabetes Care 1995, 18:292-299.
41. Haffner S.M., Valdez R.A., Mykkanen L., Stern M.P., Katz M.S. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994, 43:599-603.
42. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.